{"protocolSection":{"identificationModule":{"nctId":"NCT01854034","orgStudyIdInfo":{"id":"12-484"},"organization":{"fullName":"Massachusetts General Hospital","class":"OTHER"},"briefTitle":"Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR","officialTitle":"Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR"},"statusModule":{"statusVerifiedDate":"2018-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-07"},"primaryCompletionDateStruct":{"date":"2017-03","type":"ACTUAL"},"completionDateStruct":{"date":"2017-03","type":"ACTUAL"},"studyFirstSubmitDate":"2013-05-12","studyFirstSubmitQcDate":"2013-05-12","studyFirstPostDateStruct":{"date":"2013-05-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-02-08","resultsFirstSubmitQcDate":"2018-03-11","resultsFirstPostDateStruct":{"date":"2018-04-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-03-11","lastUpdatePostDateStruct":{"date":"2018-04-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Lecia V. Sequist","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Massachusetts General Hospital"},"leadSponsor":{"name":"Massachusetts General Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. \"Investigational\" means that the drug is being studied. It also means that the FDA has not yet approved the drug for your type of cancer or for any use outside of research studies.\n\nIt has been found that some people with NSCLC have a change (mutation) in a certain gene called the EGFR gene. This mutated gene helps cancer cells grow. The majority of NSCLC patients with EGFR mutations achieve good outcomes with erlotinib or other EGFR inhibitor therapies, with a high response rate, prolonged progression-free survival and possibly improved overall survival from therapy. However, the 4% of EGFR mutant patients that harbor an exon 20 insertion mutation historically have reaped little benefit from EGFR-directed therapy due to the low affinity of this mutation for direct EGFR inhibitors, especially erlotinib and gefitinib (see Yasuda et al, Lancet Oncol 2011). This group of patients is ideal for studying other targeted therapeutic strategies that could affect the oncogene mutation in EGFR via alternative mechanisms.\n\nAUY922 is an investigational drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies. Information from those other research studies suggests that AUY922 may be effective in killing cancer cells in patients with exon 20 insertion mutations in EGFR.\n\nThe purpose of this study is to test the safety of AUY922 and determine how well AUY922 works for participants with advanced NSCLC and exon 20 insertion mutations in EGFR.","detailedDescription":"Interested patients will be asked to undergo some screening tests and procedures to confirm that they are eligible. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that patients do not take part in the research study. If patients have had some of these tests or procedures recently, they may or may not have to be repeated. These tests and procedures include: a medical history physical exam, performance status, assessment of tumor, EKG, electrocardiogram or multigated acquisition scan, eye exam, blood draw, blood pregnancy test, urine test and collection of a piece of the stored tumor tissue.\n\nThe study treatment is given in 21 day cycles. AUY922 is given by IV (into a vein). This is called an infusion. Patients will receive an infusion of AUY922 on days 1, 8 and 15 of each cycle (once per week). The infusion will take about 60 minutes.\n\nA schedule of clinic visits for the study is summarized below.\n\nCycle 1, Day 1: physical exam, including measurement of vital signs and weight; performance status; EKG; blood draw; routine urine test Cycle 1, Day 2: EKG Cycle 1, Day 3: EKG Cycle 1, Day 8: Vital signs, performance status, EKG, questions about side effects and other medications taken Cycle 1, Day 15: Physical exam, including measurement of vital signs, performance status; EKG; blood draw; questions about side effects and other medications taken Note that in Cycle 1 patients will need to stay at (or return to) the clinic for the last EKG following the Day 1 AUY922 infusion, and come to the clinic on Days 2 and 3 for EKGs.\n\nCycle 2 and beyond, Day 1: physical exam, including measurement of vital signs and weight; performance status; EKG; blood draw; questions about side effects and other medications taken; routine urine test Cycle 2 and beyond, Day 8: Vital signs; performance status; EKG; questions about side effects and other medications taken Cycle 2 and beyond, Day 15: Physical exam, including measurement of vital signs; performance status; EKG; blood draw; questions about side effects and other medications taken.\n\nAdditional EKGs may be done at any time if the study doctor thinks it is necessary. A blood test to measure the amount of cardiac enzymes in the blood may be done whenever abnormal findings are suspected or seen on the EKG.\n\nAdditional tests and procedures:\n\n* CT or MRI scans will be done to measure the disease about every 6 weeks.\n* A blood pregnancy test, for women who can become pregnant, will be performed every 6 weeks or at any point in which pregnancy is suspected.\n* A standard eye exam will be done on Cycle 3, Day 1. Additional eye exams will be done if patients experience any eye-related symptoms, such as changes in vision.\n\nWithin 1 week after the last dose of the study drug AUY922, patients will be asked to return to the clinic. At this visit the following will be done: physical examination, performance status, EKG, ECHO or MUGA scan, blood draw, urine test, eye exam, questions about side effects and other medications taken. Patients will be asked to return to the clinic a second time so investigators can follow-up on any ongoing side effects after stopping AUY922."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"],"keywords":["Advanced disease","EGFR mutation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":29,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"AUY922 Treatment Arm","type":"EXPERIMENTAL","description":"AUY922 administered once weekly via intravenous, 70 mg/m2","interventionNames":["Drug: AUY922"]}],"interventions":[{"type":"DRUG","name":"AUY922","description":"AUY922 administered intravenously once a week at 70mg/m2","armGroupLabels":["AUY922 Treatment Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate","description":"The number of participants that achieved a response to treatment as assessed by Response Evaluation Criteria is Solid Tumors (RECIST). Response is defined as having achieved either a complete response (CR) or a partial response (PR).\n\n* Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \\< 10 mm.\n* Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"From the start of treatment until the time of disease progression, median duration of follow-up of about 3 months"}],"secondaryOutcomes":[{"measure":"Median Progression Free and Overall Survival","description":"Overall survival (OS) is measured from the start of treatment until the time of death. Progression free survival is measured from the start of treatment until the time of death or disease progression as assessed by RECIST. Progressive disease is defined as having at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions denotes disease progression.","timeFrame":"From the start of treatment until the time or death or disease progression"},{"measure":"The Number of Participants With Treatment Related Serious Adverse Events","description":"The number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) that were deemed to be possibly, probably, or definitely related to study treatment as determined by the treating physician.","timeFrame":"From the start of treatment until 28 days after the end of treatment"},{"measure":"Exon 20 EGFR Mutations Among Participants That Responded to Treatment","description":"The specific exon 20 epidermal growth factor receptor (EGFR) mutations among participants that achieved either a partial response or complete response as assessed by RECIST. The EGFR mutations were assessed from biopsies taken at baseline and then the baseline mutations were categorized by disease response.\n\n* Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \\< 10 mm.\n* Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","timeFrame":"Baseline, at the time of response"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed stage IV or recurrent NSCLC\n* Measurable disease by RECIST 1.0\n* Must have received at least one prior line of therapy for advanced lung cancer (no maximum number)\n* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Radiation within 2 weeks\n* Cytotoxic chemotherapy or monoclonal antibodies within 4 weeks\n* EGFR tyrosine kinase inhibitor within 2 weeks\n* Other small molecule inhibitor within 2 weeks\n* Experimental treatment within 30 days\n* Prior treatment with any HSP90 or HDAC inhibitor compound\n* Known and untreated brain metastases\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922\n* Unresolved diarrhea greater than or equal to CTCAE version 4, grade 1\n* Major surgery within 2 weeks of starting study drug or have not recovered from side effects of surgery\n* Known disorders due to a deficiency in bilirubin glucuronidation\n* Requiring use of therapeutic doses of warfarin (Coumadin)\n* History of long QT syndrome\n* History of clinically manifest ischemic heart disease, heart failure or left ventricular dysfunction\n* Clinically significant ECG abnormalities\n* Other clinically significant heart disease\n* Currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes\n* On a cardiac pacemaker\n* Concurrent malignancies or invasive cancers diagnosed within 3 years except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix\n* Known to be HIV positive","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Lecia Sequist, MD, MPH","affiliation":"Massachusetts General Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Beth Israel Deaconess Medical Center","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Brigham and Women's Hospital","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana-Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}}]},"referencesModule":{"references":[{"pmid":"30351341","type":"DERIVED","citation":"Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"60","lowerLimit":"31","upperLimit":"79"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"18"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"11"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}]}]},{"title":"Median Prior Lines of Therapy","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Therapies","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1","lowerLimit":"1","upperLimit":"5"}]}]}]},{"title":"Number of Participants with prior EGFR TKI","description":"epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]}]},{"title":"Baseline ECOG PS","description":"The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)\n\n* 0: Asymptomatic (Fully active, able to carry on all pre-disease activities without restriction)\n* 1: Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work)\n* 2: Symptomatic, \\<50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"0","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]},{"title":"1","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}]},{"title":"2","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate","description":"The number of participants that achieved a response to treatment as assessed by Response Evaluation Criteria is Solid Tumors (RECIST). Response is defined as having achieved either a complete response (CR) or a partial response (PR).\n\n* Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \\< 10 mm.\n* Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From the start of treatment until the time of disease progression, median duration of follow-up of about 3 months","groups":[{"id":"OG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]},{"type":"SECONDARY","title":"Median Progression Free and Overall Survival","description":"Overall survival (OS) is measured from the start of treatment until the time of death. Progression free survival is measured from the start of treatment until the time of death or disease progression as assessed by RECIST. Progressive disease is defined as having at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions denotes disease progression.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the start of treatment until the time or death or disease progression","groups":[{"id":"OG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"classes":[{"title":"Overall Survival","categories":[{"measurements":[{"groupId":"OG000","value":"9.9","lowerLimit":"4.5","upperLimit":"19.2"}]}]},{"title":"Progression Free Survival","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"1.3","upperLimit":"5.6"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Treatment Related Serious Adverse Events","description":"The number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) that were deemed to be possibly, probably, or definitely related to study treatment as determined by the treating physician.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From the start of treatment until 28 days after the end of treatment","groups":[{"id":"OG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}]},{"type":"SECONDARY","title":"Exon 20 EGFR Mutations Among Participants That Responded to Treatment","description":"The specific exon 20 epidermal growth factor receptor (EGFR) mutations among participants that achieved either a partial response or complete response as assessed by RECIST. The EGFR mutations were assessed from biopsies taken at baseline and then the baseline mutations were categorized by disease response.\n\n* Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \\< 10 mm.\n* Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, at the time of response","groups":[{"id":"OG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"classes":[{"title":"Complete Response : D770_P772dup","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Partial Response : N771insGF","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Partial Response : D770_N771insSVD","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Partial Response : P772_H773dupPH","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Partial Response : P773dup","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From baseline until 28 days after the last dose of the study drug was received (Â±7 days). Treatment is continued until: > Disease progression. > Intercurrent illness that prevents further administration of treatment, > Unacceptable adverse event(s), > Participant decides to withdraw from the study, or > General or specific changes in the participant's condition render the participant unacceptable for further treatment in the opinion of the treating investigator","description":"Serious adverse events are defined as grade 3 or higher adverse events deemed to at least possibly related to the study drug.","eventGroups":[{"id":"EG000","title":"AUY922 Treatment Arm","description":"AUY922 administered intravenously once a week at 70mg/m2","deathsNumAffected":0,"deathsNumAtRisk":29,"seriousNumAffected":6,"seriousNumAtRisk":29,"otherNumAffected":29,"otherNumAtRisk":29}],"seriousEvents":[{"term":"Eye Disorder- Other","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":29}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Allergic reaction","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Allergic rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":29}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":29}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":29}]},{"term":"Blurred vision","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":29}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":29}]},{"term":"Buttock pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":29}]},{"term":"Cholesterol high","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":29}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":29}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":29}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":23,"numAtRisk":29}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":29}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":29}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":29}]},{"term":"Edema limbs","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Eye disorders - Other, specify","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":21,"numAtRisk":29}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":23,"numAtRisk":29}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Flashing lights","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Floaters","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":29}]},{"term":"Gastroesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Gastrointestinal disorders - Other, specify","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"General disorders and administration site conditions - Other, specify","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":29}]},{"term":"Generalized muscle weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":29}]},{"term":"Hepatobiliary disorders - Other, specify","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Hoarseness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":11,"numAtRisk":29}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":29}]},{"term":"Hypomagnesemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":5,"numAtRisk":29}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":29}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Infections and infestations - Other, specify","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":29}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":29}]},{"term":"Musculoskeletal and connective tissue disorders - Other, specify","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":29}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":29}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Nervous system disorders - Other, specify","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Night blindness","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":29}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":29}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Postnasal drip","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":29}]},{"term":"Respiratory, thoracic and mediastinal disorders - Other, specify","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Skin/subcutaneous tissue disorders; Other, specify","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Surgical and medical procedures - Other, specify","organSystem":"Surgical and medical procedures","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":29}]},{"term":"Weight loss","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Lecia Van Dam Sequist, M.D.","organization":"Massachusetts General Hospital","email":"lvsequist@partners.org","phone":"617-724-4000"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2016-09-29","uploadDate":"2018-02-07T15:12","filename":"Prot_SAP_000.pdf","size":865495}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C528044","term":"5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide"}]}},"hasResults":true}